Approval · Notice of Compliance 14768 · 2015
TEVA-EXEMESTANE: Notice of Compliance 14768
Issued February 26, 2015
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 14768
- Date
- February 26, 2015
- Company
- Teva Canada LimitedToronto, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Abbreviated New Drug Submission (ANDS)
- Submission class
- Admin
- Reason
- Licensing agreement between two companies
- Therapeutic class
- Aromatase inactivator; anti-tumour agent
- Canadian reference product
- AROMASIN (Pfizer Canada Ulc)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| TEVA-EXEMESTANE | 02408473 | Cancelled Post Market |
Medicinal ingredients
- EXEMESTANE 25 MG per TAB